Literature DB >> 18602297

Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy.

Johannus Neven1, Christine Hulsbergen-van der Kaa, Jacqueline Groot-Loonen, Peter C M de Wilde, Matthais A W Merkx.   

Abstract

The case of a 4-month-old male infant treated with combined surgery and chemotherapy for an aggressive recurrent melanotic neuroectodermal tumor of infancy (MNTI) on the top of the alveolar process of the mandible with a long-term follow-up is presented. Initial treatment comprised conservative local excision and curettage of the mandible. After several local recurrences and because radical surgical excision would give gross functional and aesthetic mutilation, finally complete, long-lasting remission was achieved with adjuvant chemotherapy, according to a neuroblastoma protocol (10-year follow-up). The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to neuroblastomas. A combination of surgery and chemotherapy should be the preferred treatment in case of a recurrence MNTI because optimal functional and aesthetic outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602297     DOI: 10.1016/j.tripleo.2008.02.001

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  10 in total

1.  Mandibular melanotic neuroectodermal tumor of infancy: a role for neoadjuvant chemotherapy.

Authors:  Christopher Maroun; Ibrahim Khalifeh; Elie Alam; Pierre Abi Akl; Raya Saab; Roger V Moukarbel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-23       Impact factor: 2.503

2.  Melanotic neuroectodermal tumour of infancy (progonoma) treated by radical maxillary surgery.

Authors:  L A Renner; A E Abdulai
Journal:  Ghana Med J       Date:  2009-06

Review 3.  Melanotic neuroectodermal tumor of infancy to the skull: case-based review.

Authors:  Florian Ebel; Florian M Thieringer; Christoph Kunz; Andreas Klein-Franke; Katrin Scheinemann; Raphael Guzman; Jehuda Soleman
Journal:  Childs Nerv Syst       Date:  2020-01-17       Impact factor: 1.475

4.  Melanotic neuroectodermal tumor of infancy: A rare case report with differential diagnosis and review of the literature.

Authors:  Balaji Babu Bangi; M L Avinash Tejasvi
Journal:  Contemp Clin Dent       Date:  2012-01

5.  Melanotic neuroectodermal tumor of infancy: a rare presentation of an extremely rare neoplasm and diagnostic implications in Gombe, Nigeria.

Authors:  Babatunde Oludare Fakuade; Joshua Biodun Adeoye
Journal:  Pan Afr Med J       Date:  2017-09-04

Review 6.  Melanotic neuroectodermal tumor of infancy: discussion of a case and a review of the imaging findings.

Authors:  B Nazira; H Gupta; A K Chaturvedi; S A Rao; A Jena
Journal:  Cancer Imaging       Date:  2009-12-24       Impact factor: 3.909

7.  Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases.

Authors:  Rong-Hui Xia; Chun-Ye Zhang; Li-Zhen Wang; Yu-Hua Hu; Jing-Jing Sun; Zhen Tian; Jiang Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

8.  Melanotic neuroectodermal tumor of infancy in the maxilla.

Authors:  Daniel Falbo Martins de Souza; Daniel Isaac Sendyk; Juliana Seo; Eduardo Vasques da Fonseca; Maria da Graça Naclério-Homem; Maria Cristina Zindel Deboni
Journal:  Case Rep Dent       Date:  2013-09-08

9.  Melanotic neuroectodermal tumor of infancy in an African-indigenous patient from the Amazon: a case report.

Authors:  Thiago Pastor da Silva Pinheiro; José Thiers Carneiro; Sérgio de Melo Alves; João de Jesus Viana Pinheiro; Fabrício Mesquita Tuji
Journal:  Head Face Med       Date:  2013-11-25       Impact factor: 2.151

10.  Ototoxicity after platinum-based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy.

Authors:  Dorota Hojan-Jezierska; Anna Chomiak; Agata Czopor; Maja Matthews-Kozanecka; Anna Majewska; Marta Urbaniak-Olejnik; Teresa Matthews-Brzozowska
Journal:  Oncol Lett       Date:  2020-03-05       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.